Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

1. Laser Interstitial Thermal Therapy for Epilepsy and/or Brain Tumours: A Review of Clinical Effectiveness and Cost-Effectiveness

Laser Interstitial Thermal Therapy for Epilepsy and/or Brain Tumours: A Review of Clinical Effectiveness and Cost-Effectiveness Laser Interstitial Thermal Therapy for Epilepsy and/or Brain Tumours: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Laser Interstitial Thermal Therapy for Epilepsy and/or Brain Tumours: A Review of Clinical Effectiveness and Cost-Effectiveness Laser Interstitial Thermal Therapy for Epilepsy and/or Brain Tumours (...) : A Review of Clinical Effectiveness and Cost-Effectiveness Last updated: June 17, 2019 Project Number: RC1140-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and safety of Laser Interstitial Thermal Therapy for epilepsy and/or for brain tumours? What is the cost-effectiveness of Laser Interstitial Thermal Therapy for epilepsy and/or for brain tumours? Key Message This review provides

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Lacosamide - epilepsy medicine used to treat partial-onset seizures

Lacosamide - epilepsy medicine used to treat partial-onset seizures Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/384569/2019 EMEA/H/C/005243 Lacosamide UCB (lacosamide (...) ) An overview of Lacosamide UCB and why it is authorised in the EU What is Lacosamide UCB and what is it used for? Lacosamide UCB is an epilepsy medicine used to treat partial-onset seizures (epileptic fits starting in one specific part of the brain) in patients with epilepsy aged 4 years or older. It can be used to treat partial-onset seizures with or without secondary generalisation (where the seizure subsequently spreads to other parts of the brain). Lacosamide UCB is given on its own or combined

2019 European Medicines Agency - EPARs

3. Epilepsy among Pediatric Patients: The Use of Cannabidiol and Potential Impacts on Quality of Life

Epilepsy among Pediatric Patients: The Use of Cannabidiol and Potential Impacts on Quality of Life "Epilepsy among Pediatric Patients: The Use of Cannabidiol and Potentia" by Mary E. Schuwerk < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Chronic epilepsy can cause severe impairments with respect to physical, mental, and social aspects of a child’s life leading (...) to low self-esteem, anxiety, depression, impaired memory and attention, lack of independence, and social stigma. Controlling seizures and their negative sequelae can be challenging in those with early onset epilepsy as they are often refractory to standard therapies. A further challenge is that all currently available anti-epileptic drugs have been shown to cause adverse cognitive effects and a certain degree of toxicity. However, cannabidiol (CBD), an agent found in cannabis, has been proven

2019 Pacific University EBM Capstone Project

4. Sulthiame add-on therapy for epilepsy. (PubMed)

Sulthiame add-on therapy for epilepsy. This is an updated version of the Cochrane Review previously published in the Cochrane Database of Systematic Reviews 2015, Issue 10. Epilepsy is a common neurological condition, characterised by recurrent seizures. Most people respond to conventional antiepileptic drugs, however, around 30% will continue to experience seizures, despite treatment with multiple antiepileptic drugs. Sulthiame, also known as sultiame, is a widely used antiepileptic drug (...) in Europe and Israel. We present a summary of the evidence for the use of sulthiame as add-on therapy in epilepsy.To assess the efficacy and tolerability of sulthiame as add-on therapy for people with epilepsy of any aetiology compared with placebo or another antiepileptic drug.For the latest update, we searched the Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group's Specialized Register and CENTRAL (17 January 2019), MEDLINE Ovid (1946 to January 16, 2019

2019 Cochrane

5. Perampanel (Fycompa) - for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.

Perampanel (Fycompa) - for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy. Published 12 August 2019 www.scottishmedicines.org.uk Statement of advice SMC2218 perampanel 0.5mg/mL oral suspension (Fycompa®) Eisai Ltd 5 July 2019 Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish (...) with the patient and/or guardian or carer. Chairman Scottish Medicines Consortium ADVICE: in the absence of a submission from the holder of the marketing authorisation perampanel (Fycompa®) is not recommended for use within NHSScotland. Indication under review: for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy. The holder of the marketing authorisation has not made a submission to SMC regarding

2019 Scottish Medicines Consortium

6. Perampanel (Fycompa) - for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.

Perampanel (Fycompa) - for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy. Published 12 August 2019 1 Product update SMC2172 perampanel 0.5mg/mL oral suspension (Fycompa®) Eisai Ltd 5 July 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use (...) in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission perampanel (Fycompa®) is accepted for restricted use within NHSScotland. Indication under review: for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy. SMC restriction: use as a second-line adjunctive treatment in patients with refractory partial onset epilepsy who are unable to swallow

2019 Scottish Medicines Consortium

7. Felbamate add-on therapy for drug-resistant focal epilepsy. (PubMed)

Felbamate add-on therapy for drug-resistant focal epilepsy. This is an updated version of the Cochrane Review previously published in 2017.Epilepsy is a chronic and disabling neurological disorder, affecting approximately 1% of the population. Up to 30% of people with epilepsy have seizures that are resistant to currently available antiepileptic drugs and require treatment with multiple antiepileptic drugs in combination. Felbamate is a second-generation antiepileptic drug that can be used (...) to support the use of felbamate as an add-on therapy in people with drug-resistant focal-onset epilepsy. A large-scale, randomised controlled trial conducted over a longer period of time is required to inform clinical practice.

2019 Cochrane

8. Phenobarbitone versus phenytoin monotherapy for epilepsy: an individual participant data review. (PubMed)

Phenobarbitone versus phenytoin monotherapy for epilepsy: an individual participant data review. This is an update of a Cochrane Review first published in 2001, and last updated in 2013. This review is one in a series of Cochrane Reviews investigating pair-wise monotherapy comparisons.Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment, up to 70% of individuals (...) with active epilepsy have the potential to become seizure-free and go into long-term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy.Worldwide, particularly in the developing world, phenytoin and phenobarbitone are commonly used antiepileptic drugs, primarily because they are inexpensive. The aim of this review is to summarise data from existing trials comparing phenytoin and phenobarbitone.To review the time to treatment failure, remission and first seizure

2019 Cochrane

9. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. (PubMed)

Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. This is an update of a Cochrane Review first published in 2002 and last updated in 2017. This review is one in a series of Cochrane Reviews investigating pair-wise monotherapy comparisons.Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment, up to 70% of individuals (...) with active epilepsy have the potential to become seizure-free and go into long-term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy.Worldwide, carbamazepine and phenytoin are commonly-used broad spectrum antiepileptic drugs, suitable for most epileptic seizure types. Carbamazepine is a current first-line treatment for focal onset seizures in the USA and Europe. Phenytoin is no longer considered a first-line treatment, due to concerns over adverse events

2019 Cochrane

10. Pregabalin add-on for drug-resistant focal epilepsy. (PubMed)

Pregabalin add-on for drug-resistant focal epilepsy. Epilepsy is a common neurological disease that affects approximately 1% of the UK population. Approximately one-third of these people continue to have seizures despite drug treatment. Pregabalin is one of the newer antiepileptic drugs which have been developed to improve outcomes.This is an updated version of the Cochrane Review published in Issue 3, 2014, and includes three new studies.To assess the efficacy and tolerability of pregabalin (...) when used as an add-on treatment for drug-resistant focal epilepsy.For the latest update we searched the Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL), on 5 July 2018, MEDLINE (Ovid, 1946 to 5 July 2018), ClinicalTrials.gov (5 July 2018), and the World Health Organization International Clinical Trials Registry Platform (ICTRP, 5 July 2018), and contacted Pfizer Ltd

2019 Cochrane

11. Self-management of Epilepsy: A Systematic Review. (PubMed)

Self-management of Epilepsy: A Systematic Review. Although self-management is recommended for persons with epilepsy, its optimal strategies and effects are uncertain.To evaluate the components and efficacy of self-management interventions in the treatment of epilepsy in community-dwelling persons.English-language searches of MEDLINE, Cochrane Central Register of Controlled Trials, PsycINFO, and CINAHL in April 2018; the MEDLINE search was updated in March 2019.Randomized and nonrandomized (...) , and hospitalizations.High ROB in most studies, incomplete intervention descriptions, and studies limited to English-language publications.There is limited evidence that self-management strategies modestly improve some patient outcomes that are important to persons with epilepsy. Overall, self-management research in epilepsy is limited by the range of interventions tested, the small number of studies using self-monitoring technology, and uncertainty about components and strategies associated with benefit.U.S. Department

2019 Annals of Internal Medicine

12. Eslicarbazepine acetate (Zebinix) - epilepsy

Eslicarbazepine acetate (Zebinix) - epilepsy Final Appraisal Recommendation Advice No: 1019 – June 2019 Eslicarbazepine acetate (Zebinix ® ) 200 mg and 800 mg tablets, and 50 mg/ml oral suspension Limited submission by Eisai Ltd Additional note(s): • This advice incorporates and replaces the existing AWMSG recommendation for eslicarbazepine acetate (Zebinix ® ) as an option for restricted use within NHS Wales. Eslicarbazepine acetate should be restricted to treatment of highly refractory

2019 All Wales Medicines Strategy Group

13. Epilepsy duration and seizure outcome in epilepsy surgery: A systematic review and meta-analysis

Epilepsy duration and seizure outcome in epilepsy surgery: A systematic review and meta-analysis To conduct a systematic review and meta-analysis on the effect of earlier or later resective epilepsy surgery on seizure outcome.We searched the electronic databases PubMed, EMBASE, and Cochrane Library for studies investigating the association of epilepsy duration and seizure freedom after resective surgery. Two reviewers independently screened citations for eligibility and assessed relevant (...) studies for risk of bias. We combined data in meta-analyses using a random effects model. We assessed the certainty of evidence according to Grading of Recommendations Assessment, Development and Evaluation (GRADE).Twenty-five studies were included, 12 of which had data suitable for meta-analyses. Comparing seizure outcome if epilepsy surgery was performed before vs after 2, 5, 10, and 20 years of epilepsy duration, and comparing epilepsy duration <5 years to >10 years, we found significant effects

2019 EvidenceUpdates

14. Surgery for epilepsy. (PubMed)

Surgery for epilepsy. This is an updated version of the original Cochrane review, published in 2015.Focal epilepsies are caused by a malfunction of nerve cells localised in one part of one cerebral hemisphere. In studies, estimates of the number of individuals with focal epilepsy who do not become seizure-free despite optimal drug therapy vary between at least 20% and up to 70%. If the epileptogenic zone can be located, surgical resection offers the chance of a cure with a corresponding (...) increase in quality of life.The primary objective is to assess the overall outcome of epilepsy surgery according to evidence from randomised controlled trials.Secondary objectives are to assess the overall outcome of epilepsy surgery according to non-randomised evidence, and to identify the factors that correlate with remission of seizures postoperatively.For the latest update, we searched the following databases on 11 March 2019: Cochrane Register of Studies (CRS Web), which includes the Cochrane

2019 Cochrane

15. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. (PubMed)

Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. This is an updated version of the original Cochrane Review published in Issue 12, 2016. This review is one in a series of Cochrane Reviews investigating pair-wise monotherapy comparisons.Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment, up to 70% of individuals (...) with active epilepsy have the potential to become seizure-free and go into long-term remission shortly after starting drug therapy, the majority of which may be able to achieve remission with a single antiepileptic drug (AED).The correct choice of first-line AED for individuals with newly diagnosed seizures is of great importance and should be based on the highest-quality evidence available regarding the potential benefits and harms of various treatments for an individual.Topiramate and carbamazepine

2019 Cochrane

16. Brivaracetam add-on therapy for drug-resistant epilepsy. (PubMed)

Brivaracetam add-on therapy for drug-resistant epilepsy. Epilepsy is one of the most common neurological disorders. It is estimated that up to 30% of patients with epilepsy continue to have epileptic seizures despite treatment with an antiepileptic drug. These patients are classified as drug-resistant and require treatment with a combination of multiple antiepileptic drugs. Brivaracetam is a third-generation antiepileptic drug that is a high-affinity ligand for synaptic vesicle protein 2A (...) . This review investigates the use of brivaracetam as add-on therapy for epilepsy.To evaluate the efficacy and tolerability of brivaracetam when used as add-on treatment for people with drug-resistant epilepsy.We searched the following databases on 9 October 2018: the Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL); Medline (Ovid) 1946 to 8 October 2018; ClinicalTrials.gov; and the World

2019 Cochrane

17. Antiepileptic drugs as prophylaxis for de novo brain tumour-related epilepsy after craniotomy: a systematic review and meta-analysis of harm and benefits

Antiepileptic drugs as prophylaxis for de novo brain tumour-related epilepsy after craniotomy: a systematic review and meta-analysis of harm and benefits To investigate potential harm and benefits of antiepileptic drugs (AED) given prophylactically to prevent de novo brain tumour-related epilepsy after craniotomy.Randomised controlled trials (RCT) and retrospective studies published before 27 November 2018 were included. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (...) . This study suggests that prophylactic AED should not be administered to prevent brain tumour-related epilepsy after craniotomy.© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

2019 EvidenceUpdates

18. Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase

Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Seizures may be reduced in some severe drug-resistant epilepsies by a cannabis derivative Discover Portal Discover Portal Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Published on 26 June 2018 doi: In people with some types of severe, drug-resistant epilepsy, adding cannabidiol to their treatment may reduce seizure (...) frequency and improve quality of life compared with a placebo. The likelihood of being free from seizures for more than a year was still low, about 8%. However, an additional 12% of people had serious adverse effects with cannabidiol. These findings come from a systematic review, which included six trials in 555 patients. Most were children and adolescents with rare forms of epilepsy, and findings may not apply to other forms of the condition. The included trials were poorly reported and show some bias

2019 NIHR Dissemination Centre

19. A range of anti-epilepsy drugs are effective as first-line treatment

A range of anti-epilepsy drugs are effective as first-line treatment A range of anti-epilepsy drugs are effective as first-line treatment Discover Portal Discover Portal A range of anti-epilepsy drugs are effective as first-line treatment Published on 12 September 2017 doi: Lamotrigine and levetiracetam are emerging as first-line treatments for epilepsy, which people may be more likely to keep taking than carbamazepine. Reducing the risk of adverse events and treatment withdrawal is important (...) when selecting an anti-epilepsy drug as it usually will need to be taken long-term. This study reviewed evidence on anti-epilepsy drugs in adults and children. The drugs were compared directly or indirectly with each other. The main outcome of interest was time to withdrawal from treatment, which indicates effectiveness and tolerability. The findings support NICE recommendations to use carbamazepine or lamotrigine as first-line therapies for epilepsy with partial seizures, with levetiracetam

2019 NIHR Dissemination Centre

20. Topiramate for juvenile myoclonic epilepsy. (PubMed)

Topiramate for juvenile myoclonic epilepsy. Topiramate is a newer broad-spectrum antiepileptic drug (AED). Some studies have shown the benefits of topiramate in the treatment of juvenile myoclonic epilepsy (JME). However, there are no current systematic reviews to determine the efficacy and tolerability of topiramate in people with JME. This is an update of a Cochrane Review first published in 2015, and last updated in 2017.To evaluate the efficacy and tolerability of topiramate (...) in the treatment of JME.For the latest update, on 10 July 2018 we searched the Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group's Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid 1946- ), and ClinicalTrials.gov. We also searched ongoing trials registers, reference lists and relevant conference proceedings, and contacted study authors and pharmaceutical companies.We included randomized controlled trials (RCTs) investigating

2019 Cochrane